Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL

Gastrointestinal Cancer

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial

JAMA Oncol

Reiss KA, Xia M, Akamandisa M, D'Andrea K, Wubbenhorst B, Lord CJ, Pettitt SJ, Tutt ANJ, Brown TJ, O'Hara MH, Schneider C, Teitelbaum U, Hannan Z, Hood R, Tondon R, Vonderheide RH, Domchek SM, Nathanson KL

doi: 10.1001/jamaoncol.2026.0870

Leukemia

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

Am J Hematol

Aspas Requena G, Rodríguez-Veiga R, Gil C, Botella C, Aguiar E, Trigo F, Colorado M, Del Bernal Del Castillo T, Barragan E, Tormo M, Rodríguez Arbolí E, Serrano López J, García Boyero R, Castaño T, Herrera Puente P, Romero Riquelme MA, Sayas Lloris MJ, Algarra-Algarra L, Rodriguez-Medina C, Sossa Melo CL, Labrador Gomez J, Vives S, Salamero O, Amigo ML, Valero Nuñez M, Rojas C, Bass F, García-Fortes M, Vidriales Vicente B, Polo M, Benavente C, Madrigal MD, Espinoza M, Pérez-Encinas M, Amador Barciela ML, Bautista G, Solana-Altabella A, Cano-Ferri I, Colmenares R, García-Ramírez P, Ibáñez Alis F, Barrios García M, Rodríguez-Macías G, López M, Oliva Hernández AY, Cerveró CJ, Martínez-Cuadrón D, Chorão P, Bergua Burgues JM, Montesinos P

doi: 10.1002/ajh.70340

Multiple Myeloma (MM)

Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database

Leuk Lymphoma

Nieto MJ, Shih YH, Fang J, Qiu Y, Gentili C, Hernandez Rivera G

doi: 10.1080/10428194.2026.2702128

Multiple Myeloma (MM)

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

Lancet Haematol

Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S, DREAMM-8 investigators

doi: 10.1016/S2352-3026(25)00256-X

Lung, Respiratory and Thoracic Cancer

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial

Lancet Oncol

Hassing MJ, Billingy NE, van den Hurk CJG, van den Heuvel MM, Verberkt CA, Becker-Commissaris A, Walraven I, SYMPRO-Lung consortium

doi: 10.1016/S1470-2045(26)00305-0

Leukemia

Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia

Leukemia

Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guérin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N

doi: 10.1038/s41375-026-02867-9

Lymphoma

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin

Blood Cancer J

Ong SY, Chen L, Manzano JM, Merryman R, Shah H, Stuver R, Desai SH, LaCasce A, Falade A, Baron K, Ganesan N, Chang T, Durani U, Othman T, Armand P, Mei M, Moskowitz AJ, Herrera AF

doi: 10.1038/s41408-026-01547-2

Genitourinary Cancer

Long-term oncological outcomes from a prospective cohort of patients with localised prostate cancer

BJU Int

Baskin AS, Hoffman KE, Penson DF, Huang LC, Zhao Z, Awamlh BAHA, Joyce DD, Morgans AK, Tosoian JJ, Wallis CJD, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, O'Neil BB, Koyama T, Barocas DA

doi: 10.1111/bju.70410

Leukemia

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Br J Haematol

Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, Cappelli L, Martelli M, Breccia M

doi: 10.1111/bjh.70418

Related content

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial

Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin

Long-term oncological outcomes from a prospective cohort of patients with localised prostate cancer

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study